Second Annual
Presidential Lecture

Tuesday, May 1, 2018
5:30 – 7:00 PM
Robbins Auditorium
Welcome to the second annual Presidential Lecture, which we’ve established to highlight outstanding research being pursued at Einstein and Montefiore. Each year, a speaker from each institution will share work celebrating our partnership in innovative research.

Steven M. Safyer, M.D.
President and Chief Executive Officer
Montefiore Medicine

Allen M. Spiegel, M.D.
The Marilyn and Stanley M. Katz Dean
Albert Einstein College of Medicine
Executive Vice President and Chief Academic Officer
Montefiore Medicine
INTRODUCTION
Pamela Stanley, Ph.D., Presidential Lecture Chair
Professor, Cell Biology
The Horace W. Goldsmith Foundation Chair

WELCOMING REMARKS
Steven M. Safyer, M.D.
President and Chief Executive Officer, Montefiore Medicine

INTRODUCTION OF WILLIAM R. JACOBS, JR., PH.D.
Allen M. Spiegel, M.D.
The Marilyn and Stanley M. Katz Dean, Albert Einstein College of Medicine
Executive Vice President and Chief Academic Officer, Montefiore Medicine

Pursuing Edward Jenner’s Revenge with Recombinant Herpes Vaccine Vectors
William R. Jacobs, Jr., Ph.D.
Professor, Microbiology & Immunology; Genetics
Investigator, Howard Hughes Medical Institute
Leo and Julia Forchheimer Chair in Microbiology and Immunology

INTRODUCTION OF BETSY HEROLD, M.D.
Allen M. Spiegel, M.D.

A Paradigm-Shifting Vaccine to Prevent and Treat Herpes Simplex Virus Infections
Betsy Herold, M.D.
Professor, Pediatrics (Pediatric Infectious Disease);
Microbiology & Immunology; Obstetrics & Gynecology and Women’s Health
Harold and Muriel Block Chair in Pediatrics
Vice Chair for Research, Pediatrics
Chief, Division of Pediatric Infectious Diseases
Director, Translational Prevention Research Center

Reception: Max and Sadie Friedman Upper Lounge
William R. Jacobs, Jr., Ph.D.
Dr. Jacobs is a professor of microbiology & immunology and of genetics and an investigator at the Howard Hughes Medical Institute. He conducts pioneering research on tuberculosis (TB), which causes an estimated 1.7 million deaths worldwide each year and is caused by the bacterium *Mycobacterium tuberculosis*. He focuses on strains of *M. tuberculosis* that have developed resistance to all seven anti-TB drugs. Among other activities, his laboratory team has analyzed the *M. tuberculosis* genes responsible for drug resistance and is now identifying genes involved in *M. tuberculosis* virulence. He holds more than two dozen patents in relation to his studies to combat TB, and he and Dr. Herold have a patent pending regarding their efforts to develop a herpes vaccine.

Betsy Herold, M.D.
Dr. Herold is a professor of pediatrics and of microbiology & immunology, vice chair for research in pediatrics and division chief of pediatric infectious diseases. She has extensive experience leading collaborative multidisciplinary projects and mentoring junior faculty in basic, translational and clinical research. She directs the Translational Prevention Research Center, which focuses on preventing viral infections, particularly those that affect pediatric transplant patients. Her lab is working to define the cellular signaling pathways that HSV-2 exploits to gain entry to cells and then spread from cell to cell. To protect women from infection after their exposure to HIV and herpes viruses, the Herold lab is also developing topical pre-exposure prophylaxis (PrEP) drugs.

The collaborative effort of Drs. Herold and Jacobs offers hope for a breakthrough in preventing herpes; they’ve engineered a novel vaccine against the herpes viruses HSV-1 and HSV-2, which cause oral, ocular, neurologic and genital herpes infections. Previous efforts to develop an effective herpes vaccine were unsuccessful. By contrast, this new vaccine has shown spectacular results in animal tests: When it is given to mice or guinea pigs, it completely protects them against subsequent infection with either HSV-1 or HSV-2. Plans are now under way to assess the vaccine in phase 1 clinical trials.